Real world data show that immunotherapy leads to better overall survival outcomes than chemotherapy in patients with ...

The FDA has approved Opdivo with Yervoy for patients 12 years old and older with MSI-H or dMMR colorectal cancer.

The Food and Drug Administration (FDA) has approved Opdivo ® (nivolumab) in combination with Yervoy ® (ipilimumab) for the treatment of adult and pediatric patients aged 12 years and older with ...

The U.S. Food and Drug Administration has approved Jobevne (bevacizumab-nwgd), a biosimilar to Avastin (bevacizumab) for ...

The combination of nivolumab with ipilimumab was approved for unresectable or metastatic microsatellite instability-high (MSI ...

Liver transplants are becoming a new treatment option for certain colorectal cancer patients whose cancer has spread to their ...

The FDA approved the use of Opdivo with Yervoy in front-line colorectal cancer, while a Manhattan court junked a class action ...

A new form of tumor infiltrating lymphocyte (TIL) therapy, a form of personalized cancer immunotherapy, dramatically improved the treatment's effectiveness in patients with metastatic gastrointestinal ...

Early-onset CRC (EO-CRC) was associated with Flavonifractor plautii and increased bile acid, tryptophan, and choline ...

A team of researchers from the Rice Biotech Launch Pad at Rice University has developed an implantable "cytokine factory" ...

Korean researchers have developed an artificial intelligence (AI) model that can accurately predict the prognosis and ...

The FDA has approved Opdivo (nivolumab) in combination with Yervoy (ipilimumab) for unresectable or metastatic MSI-H/dMMR colorectal cancer.